Finch raises $53 million for microbiome capsule for C. diff

Finch Therapeutics has raised $53 million in Series C financing to support the clinical development of its microbial therapies, including CP101, an oral microbiome capsule for recurrent Clostridioides difficile infection.

The capsule — known as a Full-Spectrum Microbiota therapy — is currently being tested in the company’s PRISM3 trial for the prevention of CDI. The FDA granted Fast Track designation to CP101 last year and a breakthrough designation early in 2019.

According to a press release issued by the company, Finch hopes to expand its microbiome therapies to inflammatory bowel disease and is currently enrolling patients in a phase 2 study that will explore the efficacy of Full-Spectrum Microbiota in individuals with autism spectrum disorder (ASD).

“We are thrilled that this additional funding, coupled with the recent Breakthrough Therapy designation we received from the FDA, will enable us to accelerate our efforts to provide a new therapy to patients battling recurrent C. difficile,” Mark Smith, CEO of Finch, said in the release. “We also look forward to advancing our investigational therapies for ASD, IBD and other conditions linked to a disrupted microbiome.”

Disclosures: Smith is employed by Finch Therapeutics.

Finch Therapeutics has raised $53 million in Series C financing to support the clinical development of its microbial therapies, including CP101, an oral microbiome capsule for recurrent Clostridioides difficile infection.

The capsule — known as a Full-Spectrum Microbiota therapy — is currently being tested in the company’s PRISM3 trial for the prevention of CDI. The FDA granted Fast Track designation to CP101 last year and a breakthrough designation early in 2019.

According to a press release issued by the company, Finch hopes to expand its microbiome therapies to inflammatory bowel disease and is currently enrolling patients in a phase 2 study that will explore the efficacy of Full-Spectrum Microbiota in individuals with autism spectrum disorder (ASD).

“We are thrilled that this additional funding, coupled with the recent Breakthrough Therapy designation we received from the FDA, will enable us to accelerate our efforts to provide a new therapy to patients battling recurrent C. difficile,” Mark Smith, CEO of Finch, said in the release. “We also look forward to advancing our investigational therapies for ASD, IBD and other conditions linked to a disrupted microbiome.”

Disclosures: Smith is employed by Finch Therapeutics.

    See more from Microbiome Resource Center